S. Schmaus

805 total citations
10 papers, 449 citations indexed

About

S. Schmaus is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, S. Schmaus has authored 10 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in S. Schmaus's work include Cancer Cells and Metastasis (6 papers), TGF-β signaling in diseases (4 papers) and Glioma Diagnosis and Treatment (4 papers). S. Schmaus is often cited by papers focused on Cancer Cells and Metastasis (6 papers), TGF-β signaling in diseases (4 papers) and Glioma Diagnosis and Treatment (4 papers). S. Schmaus collaborates with scholars based in Germany. S. Schmaus's co-authors include K.-H. Schlingensiepen, H. Heinrichs, Günther Stockhammer, Anandh Balasubramaniam, Peter Hau, Piotr Jachimczak, Ashish Suri, И. Е. Повереннова, В. Е. Парфенов and N. K. Venkataramana and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Neuro-Oncology.

In The Last Decade

S. Schmaus

10 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Schmaus Germany 6 240 234 144 80 79 10 449
В. Е. Парфенов Germany 7 175 0.7× 200 0.9× 163 1.1× 64 0.8× 67 0.8× 18 404
Anuspandana Mahapatra India 7 167 0.7× 195 0.8× 163 1.1× 61 0.8× 63 0.8× 19 407
Astrid De Boeck Belgium 8 311 1.3× 219 0.9× 109 0.8× 148 1.9× 81 1.0× 10 549
Dennis Oh United States 7 183 0.8× 436 1.9× 152 1.1× 146 1.8× 140 1.8× 10 617
Kathleen S. Ensbey Australia 12 138 0.6× 251 1.1× 86 0.6× 72 0.9× 76 1.0× 22 430
Anna N. Cvrljevic Australia 5 161 0.7× 194 0.8× 117 0.8× 96 1.2× 49 0.6× 6 391
Luis R. Borlado Spain 9 105 0.4× 376 1.6× 95 0.7× 66 0.8× 97 1.2× 11 529
P. Y. Wen United States 5 182 0.8× 194 0.8× 324 2.3× 138 1.7× 81 1.0× 5 506
Sarah Gaffey United States 9 148 0.6× 152 0.6× 243 1.7× 87 1.1× 71 0.9× 22 402
Den-Mei Yang Taiwan 8 266 1.1× 260 1.1× 217 1.5× 76 0.9× 206 2.6× 11 626

Countries citing papers authored by S. Schmaus

Since Specialization
Citations

This map shows the geographic impact of S. Schmaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Schmaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Schmaus more than expected).

Fields of papers citing papers by S. Schmaus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Schmaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Schmaus. The network helps show where S. Schmaus may publish in the future.

Co-authorship network of co-authors of S. Schmaus

This figure shows the co-authorship network connecting the top 25 collaborators of S. Schmaus. A scholar is included among the top collaborators of S. Schmaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Schmaus. S. Schmaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Oettle, Helmut, Andreas Hilbig, Thomas Seufferlein, et al.. (2011). Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study. Cancer Research. 71(8_Supplement). 5506–5506. 1 indexed citations
2.
Oettle, Helmut, Andreas Hilbig, T Seufferlein, et al.. (2011). Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.. Journal of Clinical Oncology. 29(15_suppl). 2513–2513. 21 indexed citations
3.
Bogdahn, Ulrich, Peter Hau, Günther Stockhammer, et al.. (2010). Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncology. 13(1). 132–142. 331 indexed citations
4.
Oettle, Helmut, Andreas Hilbig, T Seufferlein, et al.. (2010). Trabedersen (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.. Journal of Clinical Oncology. 28(15_suppl). 2611–2611. 2 indexed citations
5.
Oettle, Helmut, Andreas Hilbig, Thomas Seufferlein, et al.. (2009). Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. Journal of Clinical Oncology. 27(15_suppl). 4619–4619. 7 indexed citations
6.
Hilbig, Andreas, Thomas Seufferlein, Thomas A. Luger, et al.. (2008). Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009. Journal of Clinical Oncology. 26(15_suppl). 4621–4621. 8 indexed citations
7.
Schmaus, S., et al.. (2007). Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors. Recent results in cancer research. 177. 137–150. 64 indexed citations
8.
Oettle, Helmut, T Seufferlein, Roland M. Schmid, et al.. (2007). Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- β2 inhibitor AP 12009. Journal of Clinical Oncology. 25(18_suppl). 4607–4607. 2 indexed citations
9.
10.
Schmaus, S., Hans Wolf, & Fritz Schwarzmann. (2004). The Reading Frame BPLF1 of Epstein-Barr Virus: A Homologue of Herpes Simplex Virus Protein VP16. Virus Genes. 29(2). 267–277. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by В. Е. Парфенов Breakdown of academic impact, for papers by Anuspandana Mahapatra Breakdown of academic impact, for papers by Astrid De Boeck Breakdown of academic impact, for papers by Dennis Oh Breakdown of academic impact, for papers by Kathleen S. Ensbey Breakdown of academic impact, for papers by Anna N. Cvrljevic Breakdown of academic impact, for papers by Luis R. Borlado Breakdown of academic impact, for papers by P. Y. Wen Breakdown of academic impact, for papers by Sarah Gaffey Breakdown of academic impact, for papers by Den-Mei Yang
Rankless by CCL
2026